Wensu Chen

Dr. Wensu Chen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
WCWensu Chen
Wensu Chen
PDPatrick Doeblin
Patrick Doeblin
SASarah Al-Tabatabaee
Sarah Al-Tabatabaee
KKKarin Klingel
Karin Klingel
RTRadu Tanacli
Radu Tanacli
SKSebastian Kelle
Sebastian Kelle
Background: The calculation of extracellular volume (ECV) in cardiac magnetic resonance requires hematocrit, limiting its applicability in clinical practice. Based on the linear relationship between hematocrit and blood T1 relaxivity, a synthetic ECV could be estimated without a blood sample. We aim to develop and test regression models for synthetic ECV without blood sampling in 1.5-T and 3.0-T scanners. Methods: A total of 1101 subjects who underwent cardiac magnetic resonance scanning with native and postcontrast T1 mapping and venous hematocrit within 24 hours were retrospectively enrolled. Subjects were randomly split into derivation (n=550) and validation (n=551) subgroups for each scanner. Different regression models were derived controlling for sex, field strength, and left ventricle/right ventricle blood pool and validated in the validation group. We performed additional validation analyses in subgroups of patients with histological validation (n=17), amyloidosis (n=29), anemia (n=185), and reduced ejection fraction (n=322). Results: In the derivation group, 8 specific models and 2 common estimate models were derived. In the validation group, using specific models, synthetic ECV had high agreement with conventional ECV (R 2 , 0.87; P <0.0001 and R 2 , 0.88, P <0.0001; −0.16% and −0.10%, left ventricle and right ventricle model, respectively). Common models also performed well (R 2 , 0.88; P <0.0001 and R 2 , 0.89, P <0.0001; −0.21% and −0.18%, left ventricle and right ventricle model, respectively). Histological validation demonstrated equal performance of synthetic and measured ECV. Synthetic ECV as calculated by the common model showed a bias in the anemia cohort significantly reduced by the specific model (−2.45 to −1.28, right ventricle common and specific model, respectively). Conclusions: Synthetic ECV provided a promising way to calculate ECV without blood sampling. Specific models could provide the most accurate value, while common models could be more suitable in routine clinical practice because of their simplicity while maintaining adequate accuracy.

1 January 2025 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
LCLei Chen
Lei Chen
BQBowen Qiu
Bowen Qiu
XDXinjia Du
Xinjia Du
JLJiahua Liu
Jiahua Liu
ZLZhongxiao Liu
Zhongxiao Liu
YLYuan Lu
Yuan Lu
Chen L, et al. Korean J Radiol. 2025 Jun;26(6):546-556. https://doi.org/10.3348/kjr.2025.0070

25 July 2024 in European Heart Journal - Imaging Methods and Practice
Verified
Journal Article
Open access
PDF file
UWUndine Ella Witt
Undine Ella Witt
MMMaximilian Leo Müller
Maximilian Leo Müller
RBRebecca Elisabeth Beyer
Rebecca Elisabeth Beyer
JWJohannes Wieditz
Johannes Wieditz
SSSusanna Salem
Susanna Salem
SKSebastian Kelle
Sebastian Kelle
Left ventricular global longitudinal strain (LV-GLS) shows promise as a marker to detect early heart failure (HF). This study sought to (i) establish cardiac magnetic resonance imaging (CMR)–derived LV-GLS cut-offs to differentiate healthy from HF for both acquisition-based and post-processing techniques, (ii) assess agreement, and (iii) provide a method to convert LV-GLS between both techniques. A secondary analysis of a prospective study enrolling healthy subjects (n = 19) and HF patients (n = 56) was conducted. LV-GLS was measured using fast strain–encoded imaging (fSENC) and feature tracking (FT). Receiver operating characteristic (ROC) analyses were performed to derive and evaluate LV-GLS cut-offs discriminating between healthy, HF with mild deformation impairment (DI), and HF with severe DI. Linear regression and Bland–Altman analyses assessed agreement. Cut-offs discriminating between healthy and HF were identified at −19.3% and −15.1% for fSENC and FT, respectively. Cut-offs of −15.8% (fSENC) and −10.8% (FT) further distinguished mild from severe DI. No significant differences in area under ROC curve were identified between fSENC and FT. Bland–Altman analysis revealed a bias of −4.01%, 95% CI −4.42, −3.50 for FT, considering fSENC as reference. Linear regression suggested a factor of 0.76 to rescale fSENC-derived LV-GLS to FT. Using this factor on fSENC-derived cut-offs yielded rescaled FT LV-GLS cut-offs of −14.7% (healthy vs. HF) and −12% (mild vs. severe DI). LV-GLS distinguishes healthy from HF with high accuracy. Each measurement technique requires distinct cut-offs, but rescaling factors facilitate conversion. An FT-based LV-GLS ≥ −15% simplifies HF detection in clinical routine.

16 January 2024 in European Heart Journal - Imaging Methods and Practice
Verified
Journal Article
Open access
PDF file
LCLei Chen
Lei Chen
ZZZeqing Zhang
Zeqing Zhang
XDXinjia Du
Xinjia Du
JLJiahua Liu
Jiahua Liu
ZLZhongxiao Liu
Zhongxiao Liu
WCWenliang Che
Wenliang Che
Recent studies have shown that extracellular volume (ECV) can also be obtained without blood sampling by the linear relationship between haematocrit (HCT) and blood pool R1 (1/T1). However, whether this relationship holds for patients with myocardial infarction is still unclear. This study established and validated an ECV model without blood sampling in ST-segment elevation myocardial infarction (STEMI) patients. A total of 398 STEMI patients who underwent cardiac magnetic resonance (CMR) examination with T1 mapping and venous HCT within 24 h were retrospectively analysed. All patients were randomly divided into a derivation group and a validation group. The mean CMR scan time was 3 days after primary percutaneous coronary intervention. In the derivation group, a synthetic HCT formula was obtained by the linear regression between HCT and blood pool R1 (R2 = 0.45, P < 0.001). The formula was used in the validation group; the results showed high concordance and correlation between synthetic ECV and conventional ECV in integral (bias = −0.12; R2 = 0.92, P < 0.001), myocardial infarction site (bias = −0.23; R2 = 0.93, P < 0.001), and non-myocardial infarction sites (bias = −0.09; R2 = 0.94, P < 0.001). In STEMI patients, synthetic ECV without blood sampling had good consistency and correlation with conventional ECV. This study might provide a convenient and accurate method to obtain the ECV from CMR to identify myocardial fibrosis.

20 February 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QZQi Zhang
Qi Zhang
RWRuili Wang
Ruili Wang
LCLei Chen
Lei Chen
WCWensu Chen
Wensu Chen
Background: Launched in March 2019, the National Centralized Drug Procurement (NCDP) initiative aimed to optimize the drug utilization framework in public healthcare facilities. Following the integration of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) into the procurement catalog, healthcare establishments in Suining swiftly transitioned to the widespread adoption of NOACs, beginning 1 March 2020.Objective: This study aims to comprehensively assess the impact of the NCDP policy on the efficacy of anticoagulation therapy, patient medication adherence, and the incidence of hemorrhagic events in individuals with non-valvular atrial fibrillation (NVAF) residing in Suining. The analysis seeks to elucidate the broader impacts of the NCDP policy on this patient demographic.Methods: This study analyzed patient hospitalization records from the Department of Cardiology at Suining County People’s Hospital, spanning 1 January 2017, to 30 June 2022. The dataset included demographic details (age, sex), type of health insurance, year of admission, hospitalization expenses, and comprehensive information on anticoagulant therapy utilization. The CHA2DS2-VASc scoring system, an established risk assessment tool, was used to evaluate stroke risk in NVAF patients. Patients with a CHA2DS2-VASc score of 2 or higher were categorized as high-risk, while those with scores below 2 were considered medium or low-risk.Results: 1. Treatment Cost Analysis: The study included 3,986 patients diagnosed with NVAF. Following the implementation of the NCDP policy, a significant increase in the average treatment cost for hospitalized patients was observed, rising from 8,900.57 ± 9,023.02 CNY to 9,829.99 ± 10,886.87 CNY (p < 0.001). 2. Oral Anticoagulant Utilization: Overall, oral anticoagulant use increased from 40.02% to 61.33% post-NCDP (p < 0.001). Specifically, NOAC utilization among patients dramatically rose from 15.41% to 90.99% (p < 0.001). 3. Hemorrhagic Events: There was a significant decrease in hemorrhagic events following the NCDP policy, from 1.88% to 0.66% (p = 0.01). Hypertension [OR = 1.979, 95% CI (1.132, 3.462), p = 0.017], history of stroke [OR = 1.375, 95% CI (1.023, 1.847), p = 0.035], age ≥65 years [OR = 0.339, 95% CI (0.188, 0.612), p < 0.001], combination therapy of anticoagulants and antiplatelets [OR = 3.620, 95% CI (1.752, 7.480), p < 0.001], hepatic and renal insufficiency [OR = 4.294, 95% CI (2.28, 8.084), p < 0.001], and the NCDP policy [OR = 0.295, 95% CI (0.115, 0.753), p = 0.011] are significant risk factors for bleeding in patients with atrial fibrillation. 4. Re-hospitalization and Anticoagulant Use: Among the 219 patients requiring re-hospitalization, there was a notable increase in anticoagulant usage post-NCDP, from 36.07% to 59.82% (p < 0.001). NOACs, in particular, saw a substantial rise in usage among these patients, from 11.39% to 80.92% (p < 0.001). 5. Anticoagulant Type Change: The NCDP policy [OR = 28.223, 95% CI (13.148, 60.585), p < 0.001] and bleeding events [OR = 27.772, 95% CI (3.213, 240.026), p = 0.003] were significant factors influencing the alteration of anticoagulant medications in patients.Conclusion: The NCDP policy has markedly improved anticoagulation management in patients with AF. This policy has played a crucial role in enhancing medication adherence and significantly reducing the incidence of hemorrhagic events among these patients. Additionally, the NCDP policy has proven to be a key factor in guiding the selection and modification of anticoagulant therapies in the AF patient population.

8 September 2023 in European Heart Journal - Imaging Methods and Practice
Verified
Journal Article
Open access
PDF file
WCWensu Chen
Wensu Chen
AFAlessandro Faragli
Alessandro Faragli
CGCollin Goetze
Collin Goetze
VZVictoria Zieschang
Victoria Zieschang
KWKarl Jakob Weiss
Karl Jakob Weiss
PDPatrick Doeblin
Patrick Doeblin
Cardiac magnetic resonance (CMR) T1 relaxation time mapping is an established technique primarily used to identify diffuse interstitial fibrosis and oedema. The myocardial extracellular volume (ECV) can be calculated from pre- and post-contrast T1 relaxation times and is a reproducible parametric index of the proportion of volume occupied by non-cardiomyocyte components in myocardial tissue. The conventional calculation of the ECV requires blood sampling to measure the haematocrit (HCT). Given the high variability of the HCT, the blood collection is recommended within 24 h of the CMR scan, limiting its applicability and posing a barrier to the clinical routine use of ECV measurements. In recent years, several research groups have proposed a method to determine the ECV by CMR without blood sampling. This is based on the inverse relationship between the T1 relaxation rate (R1) of blood and the HCT. Consequently, a ‘synthetic’ HCT could be estimated from the native blood R1, avoiding blood sampling. We performed a review and meta-analysis of published studies on synthetic ECV, as well as a secondary analysis of previously published data to examine the effect of the chosen regression modell on bias. While, overall, a good correlation and little bias between synthetic and conventional ECV were found in these studies, questions regarding its accuracy remain. Synthetic HCT and ECV can provide a ‘non-invasive’ quantitative measurement of the myocardium’s extracellular space when timely HCT measurements are not available and large alterations in ECV are expected, such as in cardiac amyloidosis. Due to the dependency of T1 relaxation times on the local setup, calculation of local formulas using linear regression is recommended, which can be easily performed using available data. For the establishment of a local model, ∼500 patients with measured haematocrit (HCT) and left ventricular T1 relaxation rate (R1 = 1/T1) should be available and split evenly into derivation and validation data sets. The regression parameters from the derivation data is used for the estimation of synthetic HCT, which is then used for the calculation of the synthetic extracellular volume (ECV) instead of the measured HCT.